Should I buy or sell Illumina stock right now?

19 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 2 sell ratings, 9 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ILMN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ILMN, but not buy additional shares or sell existing shares. View ILMN analyst ratings or view top-rated stocks .

What is Illumina's stock price target for 2024?

19 analysts have issued 1 year target prices for Illumina's shares. Their ILMN share price targets range from $100.00 to $253.00. On average, they predict the company's stock price to reach $167.70 in the next year. This suggests a possible upside of 42.1% from the stock's current price. View analysts price targets for ILMN or view top-rated stocks among Wall Street analysts .

How have ILMN shares performed in 2024?

Illumina's stock was trading at $139.24 at the beginning of the year. Since then, ILMN stock has decreased by 15.3% and is now trading at $118.00. View the best growth stocks for 2024 here .

When is Illumina's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our ILMN earnings forecast .

How can I listen to Illumina's earnings call?

Illumina will be holding an earnings conference call on Thursday, May 2nd at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link .

How were Illumina's earnings last quarter?

Illumina, Inc. (NASDAQ:ILMN) released its quarterly earnings data on Thursday, February, 8th. The life sciences company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.01 by $0.13. The life sciences company had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.09 billion. Illumina had a negative net margin of 25.78% and a positive trailing twelve-month return on equity of 2.20%. The firm's quarterly revenue was up 3.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.14 earnings per share. Read the conference call transcript .

What ETFs hold Illumina's stock?

ETFs with the largest weight of Illumina (NASDAQ:ILMN) stock in their portfolio include First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) , VanEck Biotech ETF (BBH) , Global X Telemedicine & Digital Health ETF (EDOC) , First Trust NYSE Arca Biotechnology Index Fund (FBT) , iShares Biotechnology ETF (IBB) , Invesco Nasdaq Biotechnology ETF (IBBQ) , Global X Genomics & Biotechnology ETF (GNOM) and Principal Healthcare Innovators ETF (BTEC) .

What guidance has Illumina issued on next quarter's earnings?

Illumina updated its FY 2024 earnings guidance on Tuesday, April, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $4.4 billion-$4.4 billion, compared to the consensus revenue estimate of $4.5 billion.

What is Francis deSouza's approval rating as Illumina's CEO?

496 employees have rated Illumina Chief Executive Officer Francis deSouza on Glassdoor.com . Francis deSouza has an approval rating of 92% among the company's employees. This puts Francis deSouza in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Illumina own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA) , Alibaba Group (BABA) , Tesla (TSLA) , Netflix (NFLX) , Walt Disney (DIS) , PayPal (PYPL) , Salesforce (CRM) , Adobe (ADBE) , Visa (V) and Micron Technology (MU) .

Who are Illumina's major shareholders?

Illumina's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Douglas Lane & Associates LLC (0.16%), CWM LLC (0.04%), Los Angeles Capital Management LLC (0.03%), Czech National Bank (0.02%), 180 Wealth Advisors LLC (0.01%) and Partnership Wealth Management LLC (0.01%). Insiders that own company stock include Aimee L Hoyt , Alexander Aravanis , Charles Dadswell , Jacob Thaysen, Jay T Flatley , Phillip G Febbo , Susan H Tousi and Susan H Tousi . View institutional ownership trends .

How do I buy shares of Illumina?

Shares of ILMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Does Illumina have any subsidiaries?

The following companies are subsidiares of Illumina: Advanced Liquid Logic Inc., Affomix Corporation, BlueBee, BlueBee Belgium BVBA, BlueBee Holding BV, BlueGnome Ltd, BlueGnome Ltd., Conexio Genomics, Conexio Genomics Pty Ltd., Edico Genome, Emedgene Inc., Emedgene Technologies Ltd, Enancio, Enancio SAS, Epicentre Biotechnologies, GRAIL LLC, GenoLogics, Grail, Helixis, Illumina (China) Scientific Co Ltd, Illumina AB, Illumina Australia Pty. Ltd., Illumina Belgium BVBA, Illumina Brasil Produtos de Biotecnologia Ltda., Illumina Cambridge Ltd., Illumina Canada ULC, Illumina Denmark ApS, Illumina Finland Oy, Illumina France Sarl, Illumina GmbH, Illumina Hong Kong Limited, Illumina India Biotechnology Private Limited, Illumina Ireland Commercial Limited, Illumina Italy S.r.l., Illumina K.K. Japan, Illumina Korea Ltd., Illumina Netherlands B.V., Illumina New Zealand Limited, Illumina Norway AS, Illumina Productos de Espana S.L.U., Illumina Rus LLC, Illumina Shanghai (Trading) Co Ltd Beijing Branch, Illumina Shanghai (Trading) Co. Ltd., Illumina Singapore Pte. Ltd., Illumina Software Inc., Illumina Switzerland GmbH, Illumina US Manufacturing Operations Inc., Liquid Logic, Moleculo, NextBio, Solexa, Verinata Health, Verinata Health Inc., and thromboDx BV. Read More

NASDAQ:ILMN

Illumina (ILMN) Stock Price, News & Analysis

→ “Forget Tesla, this is Elon’s Next Big Thing” (From InvestorPlace) (Ad)

Free ILMN Stock Alerts

$117.88

-3.28 (-2.71%)

(As of 10:46 AM ET)

Compare

Today's Range: $116.83
▼
$119.56
50-Day Range: $121.16
▼
$146.07
52-Week Range: $89.00
▼
$232.23

Volume: 499,347 shs
Average Volume: 1.74 million shs
Market Capitalization: $18.77 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $167.70

Get Illumina alerts:

Illumina MarketRank™ Stock Analysis

Analyst Rating: Hold
2.32 Rating Score
Upside/Downside: 42.1% Upside
$167.70 Price Target
Short Interest: Healthy
3.32% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.11
Upright™ Environmental Score
News Sentiment: 0.53
Based on 31 Articles This Week
Insider Trading: Acquiring Shares
$991,676 Bought Last Quarter
Proj. Earnings Growth: 162.64%
From $0.91 to $2.39 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.62 out of 5 stars

Medical Sector

32nd out of 928 stocks

Analytical Instruments Industry

1st out of 28 stocks

3.2

Analyst's Opinion

Consensus Rating
Illumina has received a consensus rating of Hold. The company's average rating score is 2.32, and is based on 8 buy ratings, 9 hold ratings, and 2 sell ratings.
Amount of Analyst Coverage
Illumina has only been the subject of 4 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
3.32% of the outstanding shares of Illumina have been sold short.
Short Interest Ratio / Days to Cover
Illumina has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Illumina has recently increased by 1.34%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Illumina does not currently pay a dividend.
Dividend Growth
Illumina does not have a long track record of dividend growth.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Illumina has received a 61.69% net impact score from Upright. Illumina seems to create the most significant positive value in categories "Taxes", "Jobs", and "Physical diseases". The positive contribution in the "Physical diseases" impact category is mostly driven by its "Laboratory reagents", "DNA sequencers", and "Laboratory reagents for cells" products. See details.
Environmental Sustainability
The Environmental Impact score for Illumina is -1.11.

3.1

News and Social Media Coverage

News Sentiment
Illumina has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 31 news articles for Illumina this week, compared to 16 articles on an average week.
Search Interest
36 people have searched for ILMN on MarketBeat in the last 30 days. This is an increase of 3% compared to the previous 30 days.
MarketBeat Follows
15 people have added Illumina to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Illumina insiders have bought more of their company's stock than they have sold. Specifically, they have bought $991,676.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 0.17% of the stock of Illumina is held by insiders.
Percentage Held by Institutions
89.42% of the stock of Illumina is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Illumina are expected to grow by 162.64% in the coming year, from $0.91 to $2.39 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Illumina is -16.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Illumina is -16.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Illumina has a P/B Ratio of 3.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

REVEALED: Elon Musk’s Secret A.I. Facility?

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

Click here to see the details because there’s a lot of money at stake.

About Illumina Stock (NASDAQ:ILMN)

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

ILMN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ILMN Stock News Headlines

April 12, 2024 | marketwatch.com

EU Approves Illumina's Plan to Shed Cancer-Test Maker Grail -- 2nd Update

April 12, 2024 | marketwatch.com

EU Approves Illumina's Plan to Shed Cancer-Test Maker Grail -- Update

April 16, 2024 | InvestorPlace (Ad)

“Forget Tesla, this is Elon’s Next Big Thing”

According to Forbes, this breakthrough could define the future of AI. Most people don’t know about it… Because it was found 750 miles away from Silicon Valley.

April 12, 2024 | markets.businessinsider.com

Illumina's Divestment Plan For Grail Receives Approval From European Commission

April 12, 2024 | markets.businessinsider.com

Illumina (ILMN) Maintains Strong Guidance and Strategic Leadership Appointments

April 12, 2024 | msn.com

Illumina’s Grail divestment approved by EU

April 12, 2024 | prnewswire.com

Illumina's planned divestment of GRAIL approved by the European Commission

April 12, 2024 | reuters.com

EU approves Illumina's plan to divest cancer test maker Grail

April 16, 2024 | InvestorPlace (Ad)

REVEALED: Elon Musk’s Secret A.I. Facility?

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

April 11, 2024 | americanbankingnews.com

Barclays Boosts Illumina (NASDAQ:ILMN) Price Target to $100.00

April 11, 2024 | americanbankingnews.com

Illumina's (ILMN) "Overweight" Rating Reaffirmed at Stephens

April 10, 2024 | msn.com

Illumina gets two new executives as the San Diego biotech revamps its C-suite

April 10, 2024 | americanbankingnews.com

Illumina (NASDAQ:ILMN) Receives Outperform Rating from Royal Bank of Canada

April 9, 2024 | msn.com

Illumina CFO Goswami to depart, Summit Therapeutics' Dhingra named successor

April 9, 2024 | markets.businessinsider.com

Illumina Appoints Ankur Dhingra CFO, Reaffirms Q1 And FY24 Outlook

April 9, 2024 | reuters.com

Illumina CFO Goswami to depart, Summit Therapeutics' Dhingra named successor

April 9, 2024 | prnewswire.com

Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer

April 9, 2024 | theglobeandmail.com

Stocks Mixed Before Wednesday’s US CPI Report

April 8, 2024 | markets.businessinsider.com

Jim Cramer Isn't Going With This Tech Company: 'It's Complicated. I'm A Nvidia Guy'

April 5, 2024 | finance.yahoo.com

Why More Clinical Labs Are Turning to Whole-Genome Sequencing for Cancer

April 5, 2024 | investorplace.com

Nasdaq's Nosebleed Section: 3 Expensive Stocks to Sell Before It's Too Late

April 4, 2024 | finance.yahoo.com

Illumina to Announce First Quarter 2024 Financial Results on Thursday, May 2, 2024

April 2, 2024 | finance.yahoo.com

Giving Students a New Window on Genomic Technologies

March 31, 2024 | financialpost.com

McWhorter Foundation Combatting Nelson Peltz Illuminates The Hero In Us All: A Disney Vision for Diversity Within & Beyond The Boardroom

March 30, 2024 | nasdaq.com

May 10th Options Now Available For Illumina (ILMN)

March 29, 2024 | ca.finance.yahoo.com

ILMN Apr 2024 121.000 put

March 27, 2024 | finance.yahoo.com

Is Illumina, Inc. (NASDAQ:ILMN) Trading At A 36% Discount?

See More Headlines

Receive ILMN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Illumina and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/08/2024
Today: 4/16/2024
Next Earnings (Confirmed): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Analytical instruments
Sub-Industry: Life Sciences Tools & Services
Current Symbol: NASDAQ:ILMN
CUSIP: 45232710
CIK: 1110803
Web: www.illumina.com
Phone: (858) 202-4500
Fax: 858-202-4766
Employees: 9,300
Year Founded: 1998

Price Target and Rating

Average Stock Price Target: $167.70
High Stock Price Target: $253.00
Low Stock Price Target: $100.00
Potential Upside/Downside: +38.4%
Consensus Rating: Hold
Rating Score (0-4): 2.32
Research Coverage: 19 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($7.34)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 133.14
P/E Growth: N/A
Net Income: $-1,161,000,000.00
Net Margins: -25.78%
Pretax Margin: -24.80%
Return on Equity: 2.20%
Return on Assets: 1.25%

Debt

Debt-to-Equity Ratio: 0.26
Current Ratio: 1.66
Quick Ratio: 1.29

Sales & Book Value

Annual Sales: $4.50 billion
Price / Sales: 4.28
Cash Flow: $3.42 per share
Price / Cash Flow: 35.46
Book Value: $36.18 per share
Price / Book: 3.35

Miscellaneous

Outstanding Shares: 159,255,000
Free Float: 158,984,000
Market Cap: $19.30 billion
Optionable: Optionable
Beta: 1.19

Social Links

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. Joydeep Goswami M.B.A. (Age 53)
Ph.D., CFO, Chief Strategy & Corporate Development Officer
Comp: $787.3k
Mr. Jacob Thaysen Ph.D. (Age 49)
CEO & Director
Stephanie Campos
President
Mr. Kevin Carl Pegels (Age 57)
Chief of Global Operations
Mr. Scott Ericksen (Age 52)
VP & Chief Accounting Officer
Dr. Steven Barnard Ph.D.
Chief Technology Officer
Ms. Carissa L. Rollins (Age 54)
Chief Information Officer
Ms. Sallilyn Schwartz
Vice President of Investor Relations
Mr. Charles E. Dadswell Esq. (Age 65)
Senior VP & General Counsel
Comp: $1.06M
Ms. Kathryne Gambrell Reeves (Age 55)
Chief Marketing Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

Should I Buy Illumina Stock? ILMN Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Illumina, Inc.:

Illumina has a positive return on equity, indicating efficient use of shareholder funds to generate profits.
The company offers innovative sequencing and array-based solutions for genetic and genomic analysis, catering to a growing market demand for advanced genetic research tools.
Recent insider buying activity, such as CEO Jacob Thaysen purchasing shares, can signal confidence in the company's future prospects.
Illumina's revenue growth of 3.6% year-over-year demonstrates the company's ability to increase its top line despite market challenges.
With a 52-week high of $232.88, the stock has shown potential for strong price performance, attracting investors seeking capital appreciation.

Cons

Investors should be bearish about investing in Illumina, Inc. for these reasons:

Illumina's negative net margin of 25.78% may raise concerns about the company's profitability and cost management.
The stock ownership by institutional investors at 89.42% could lead to limited influence for individual retail investors in decision-making processes.
While revenue growth is positive, the company's earnings per share (EPS) of $0.14 for the quarter fell short of analysts' expectations, indicating potential volatility in financial performance.
Market analysts predict a lower EPS of 0.91 for the current year, suggesting potential challenges in meeting earnings targets and market expectations.
Investors should consider the competitive landscape in the life sciences tools & services industry, where Illumina operates, as it may impact the company's market position and growth prospects.

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, April 11, 2024. Please send any questions or comments about these Illumina pros and cons to contact@marketbeat.com.

ILMN Stock Analysis - Frequently Asked Questions

Should I buy or sell Illumina stock right now?: 19 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 2 sell ratings, 9 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ILMN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ILMN, but not buy additional shares or sell existing shares.
View ILMN analyst ratings or view top-rated stocks.
What is Illumina's stock price target for 2024?: 19 analysts have issued 1 year target prices for Illumina's shares. Their ILMN share price targets range from $100.00 to $253.00. On average, they predict the company's stock price to reach $167.70 in the next year. This suggests a possible upside of 42.1% from the stock's current price.
View analysts price targets for ILMN or view top-rated stocks among Wall Street analysts.
How have ILMN shares performed in 2024?: Illumina's stock was trading at $139.24 at the beginning of the year. Since then, ILMN stock has decreased by 15.3% and is now trading at $118.00.
View the best growth stocks for 2024 here.
When is Illumina's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our ILMN earnings forecast.
How can I listen to Illumina's earnings call?: Illumina will be holding an earnings conference call on Thursday, May 2nd at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link.
How were Illumina's earnings last quarter?: Illumina, Inc. (NASDAQ:ILMN) released its quarterly earnings data on Thursday, February, 8th. The life sciences company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.01 by $0.13. The life sciences company had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.09 billion. Illumina had a negative net margin of 25.78% and a positive trailing twelve-month return on equity of 2.20%. The firm's quarterly revenue was up 3.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.14 earnings per share.
Read the conference call transcript.
What ETFs hold Illumina's stock?: ETFs with the largest weight of Illumina (NASDAQ:ILMN) stock in their portfolio include First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), VanEck Biotech ETF (BBH), Global X Telemedicine & Digital Health ETF (EDOC), First Trust NYSE Arca Biotechnology Index Fund (FBT), iShares Biotechnology ETF (IBB), Invesco Nasdaq Biotechnology ETF (IBBQ), Global X Genomics & Biotechnology ETF (GNOM) and Principal Healthcare Innovators ETF (BTEC).

What guidance has Illumina issued on next quarter's earnings?: Illumina updated its FY 2024 earnings guidance on Tuesday, April, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $4.4 billion-$4.4 billion, compared to the consensus revenue estimate of $4.5 billion.
What is Francis deSouza's approval rating as Illumina's CEO?: 496 employees have rated Illumina Chief Executive Officer Francis deSouza on Glassdoor.com. Francis deSouza has an approval rating of 92% among the company's employees. This puts Francis deSouza in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Illumina own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Netflix (NFLX), Walt Disney (DIS), PayPal (PYPL), Salesforce (CRM), Adobe (ADBE), Visa (V) and Micron Technology (MU).
Who are Illumina's major shareholders?: Illumina's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Douglas Lane & Associates LLC (0.16%), CWM LLC (0.04%), Los Angeles Capital Management LLC (0.03%), Czech National Bank (0.02%), 180 Wealth Advisors LLC (0.01%) and Partnership Wealth Management LLC (0.01%). Insiders that own company stock include Aimee L Hoyt, Alexander Aravanis, Charles Dadswell, Jacob Thaysen, Jay T Flatley, Phillip G Febbo, Susan H Tousi and Susan H Tousi.
View institutional ownership trends.
How do I buy shares of Illumina?: Shares of ILMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
Does Illumina have any subsidiaries?: The following companies are subsidiares of Illumina: Advanced Liquid Logic Inc., Affomix Corporation, BlueBee, BlueBee Belgium BVBA, BlueBee Holding BV, BlueGnome Ltd, BlueGnome Ltd., Conexio Genomics, Conexio Genomics Pty Ltd., Edico Genome, Emedgene Inc., Emedgene Technologies Ltd, Enancio, Enancio SAS, Epicentre Biotechnologies, GRAIL LLC, GenoLogics, Grail, Helixis, Illumina (China) Scientific Co Ltd, Illumina AB, Illumina Australia Pty. Ltd., Illumina Belgium BVBA, Illumina Brasil Produtos de Biotecnologia Ltda., Illumina Cambridge Ltd., Illumina Canada ULC, Illumina Denmark ApS, Illumina Finland Oy, Illumina France Sarl, Illumina GmbH, Illumina Hong Kong Limited, Illumina India Biotechnology Private Limited, Illumina Ireland Commercial Limited, Illumina Italy S.r.l., Illumina K.K. Japan, Illumina Korea Ltd., Illumina Netherlands B.V., Illumina New Zealand Limited, Illumina Norway AS, Illumina Productos de Espana S.L.U., Illumina Rus LLC, Illumina Shanghai (Trading) Co Ltd Beijing Branch, Illumina Shanghai (Trading) Co. Ltd., Illumina Singapore Pte. Ltd., Illumina Software Inc., Illumina Switzerland GmbH, Illumina US Manufacturing Operations Inc., Liquid Logic, Moleculo, NextBio, Solexa, Verinata Health, Verinata Health Inc., and thromboDx BV.
Read More

This page (NASDAQ:ILMN) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial